PD-1/PD-L1 axis in lung cancer

Por Santini, Fernando C., Hellmann, Matthew D.
Publicado no Cancer J (2018)

Atezolizumab for the treatment of non-small cell lung cancer

Por Santini, Fernando C., Rudin, Charles M.
Publicado no Expert Rev Clin Pharmacol (2017)

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Por Santini, Fernando C., Kunte, Siddharth, Drilon, Alexander
Publicado no Transl Lung Cancer Res (2017)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

Por Sabari, Joshua K, Santini, Fernando C, Schram, Alison M, Bergagnini, Isabella, Chen, Ruqin, Mrad, Chebli, Lai, W Victoria, Arbour, Kathryn C, Drilon, Alexander
Publicado no Onco Targets Ther (2017)

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer

Por Chaft, Jamie E., Dagogo-Jack, Ibiayi, Santini, Fernando C., Eng, Juliana, Yeap, Beow Y., Izar, Benjamin, Chin, Emily, Jones, David R., Kris, Mark G., Shaw, Alice T., Gainor, Justin F.
Publicado no Lung Cancer (2018)

Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC

Por Santini, Fernando C., Rizvi, Hira, Plodkowski, Andrew J., Ni, Andy, Lacouture, Mario E., Gambarin-Gelwan, Maya, Wilkins, Olivia, Panora, Elizabeth, Halpenny, Darragh F., Long, Niamh M., Kris, Mark G., Rudin, Charles M., Chaft, Jamie E., Hellmann, Matthew D.
Publicado no Cancer Immunol Res (2018)